Lucent Diagnostics has launched LucentAD Complete, a novel multi-marker blood test designed to enhance the detection of Alzheimer’s Disease (AD). This test addresses limitations of existing diagnostic methods, particularly the uncertainty associated with the “intermediate zone” in single-marker tests like plasma p-Tau 217.
LucentAD Complete analyzes five AD-related biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP) using a proprietary algorithm, resulting in significantly improved amyloid classification compared to single-marker tests. Clinical trials involving over 1,000 patients demonstrated the test’s ability to reduce the number of individuals falling into the intermediate zone by threefold. This translates to more conclusive results and a reduced need for invasive procedures like lumbar punctures or expensive amyloid PET scans.
The development of LucentAD Complete was supported by the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator. Experts recognize the test’s multi-marker approach as a significant advancement in blood-based AD testing, aligning with the understanding that Alzheimer’s is a complex disease influenced by multiple factors.
Lucent Diagnostics, a brand under Quanterix Corporation, is committed to delivering innovative tools for early cognitive disease detection. Their ultra-sensitive Simoa® technology bridges the gap between research and clinical practice, providing valuable resources for both institutions and healthcare providers. With extensive experience in neurology research, Quanterix, through Lucent Diagnostics, aims to revolutionize the landscape of cognitive disease management.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
